NEW YORK: Quintiles Transnational Corporation, which provides clinical trials services to pharmaceutical and biotechnology companies, has selected Ogilvy PR for a global outreach effort.
Ogilvy replaces an unnamed agency that has worked with the company for the past 10 years, and which was one of the finalists in the competitive pitch. Terms were not disclosed.
Pat Grebe, VP of corporate communication for Quintiles, noted that Ogilvy would help raise the company's visibility among potential customers and the media. "A lot of people don't know Quintiles," she said, adding the campaign would promote the company's core services and its partnerships with pharma and biotech companies. Competitors include IMS Health and Covance.
Ogilvy is currently developing a strategic communications plan for the b-to-b company, which has worked on the top 30 global drug brands, according to Grebe. The agency is handling the account through its New York-based corporate practice.
The company operates three business groups that focus on clinical trial support in the pre-approval phase, marketing and sales consulting to help bring products to market, and helping clients develop non-traditional alliances during the product development process.
Quintiles also owns drug research firm Verispan as part of a joint venture with McKesson Corporation.
PR management consultant Jerry Swerling managed the review for Quintiles.